Background People with intellectual disability (ID) frequently use antipsychotic drugs on an off-label base, often for many years. Physicians' decisions to discontinue these drugs not only depend on patient characteristics, like the presence of mental or behavioural disorders, but also on environmental factors, such as inappropriate living circumstances, and on attitudes, knowledge and beliefs of staff, clients and their representatives towards the effects of antipsychotic drug use. In this study, we therefore investigated the influence of participant and settingrelated factors on decisions of physicians not to discontinue off-label prescribed antipsychotics. Methods The study took place in living facilities of six service providers for people with ID spread over the Netherlands and staffed with support professionals, nurses, behavioural scientist and physicians and was part of an antipsychotics discontinuation trial. ID physicians had to decide whether the off-label use of antipsychotics could be discontinued.
the off-label use of antipsychotics varied largely between the service providers. Conclusions The prevalence of antipsychotic drug use for off-label indications in people with ID remains high. The results of this study indicate that there is a large variation in clinical practice of physicians regarding discontinuation of long-term antipsychotic drug prescriptions, which may be partially related to environmental factors as setting culture and attitudes of staff towards off-label antipsychotic drug use in persons with ID.
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Background
People with intellectual disability (ID) are at high risk of medication use, in particular, psychotropic drugs (Sheehan et al. 2015 , O'Dwyer et al. 2016 . Because of the risk of drug interactions caused by multiple drug use and the increased risk for the occurrence of side effects in people with ID (Matson, Mahan 2010 , de Kuijper et al. 2013 , unnecessary use should be reduced as much as possible. Especially prescriptions that are not supported by scientific evidence, for example, the use of antipsychotic drugs for challenging behaviours, should according to guidelines be limited to a short period (Deb, Kwok, Bertelli, Salvador-Carulla, Bradley, Torr et al. 2009 ). Despite these recommendations and the growing awareness of clinicians that antipsychotics should not be prescribed long-term on an off-label base, this still frequently is the case in people with ID (Sheehan et al. 2015 , Matson, Neal 2009 , Scheifes et al. 2013 , Glover et al. 2014 .
Physicians may be hesitant to discontinue longterm off-label used antipsychotics, because of the fear to unmask symptoms of mental and behavioural disorders or to induce withdrawal symptoms in their patients (Ahmed, Fraser, Kerr, Kiernan, Emerson, Robertson et al. 2000 , Matson, Mahan 2010 . However, the likelihood that physicians may decide to discontinue may only partially be related to the patient's mental health status. Setting-related and staff-related factors may also play a prominent role, such as setting policies regarding restrictive measures, attitudes, knowledge and beliefs of clients, family and staff concerning the effects of antipsychotics in people with ID and attitudes of nursing staff towards challenging behaviour of their clients (Ahmed, Fraser, Kerr, Kiernan, Emerson, Robertson et al. 2000) . Previous studies have shown that staff-related factors like lack of knowledge regarding symptoms of mental disorders and effects of psychotropic drug use and attitudes towards the managing of behavioural problems were associated with the prescription of psychotropic drugs (Luchins et al. 1993 , Singh, Ellis, Donatelli, Williams, Ricketts, Goza et al. 1996 , Christian et al. 1999 . Besides, studies in children, adults and elderly have shown differences between settings and between physicians in prescription patterns of psychotropic drugs. The differences were related to setting culture, for example, academic versus non-academic, lack of alternative treatments and beliefs of physicians with regard to reasons for off-label antipsychotic drug use (Eguale et al. 2012 , Kishimoto et al. 2013 , Chang, Kim 2014 , Latimer, Naidu, Moodie, Clark, Malla, Tamblyn et al. 2014 , Tang et al. 2016 , Arora, Knowles, Gomes, Mamdani, Juurlink, Carlisle et al. 2016 .
Therefore, we aimed to investigate what reasons physicians have for ongoing off-label prescriptions of antipsychotics in people with ID and which participant and setting-related factors may influence their decisions whether or not to discontinue.
Methods

Study setting and participants
The study took place in residential facilities of six service providers for people with ID spread over the Netherlands. The facilities offer 24 h a day care and are organised in units of 4-12 residents supported by teams of support professionals or nurses (four to eight full-time employments). Residents were children, adolescents or adults. All visited schools, sheltered day care centres or sheltered employments. Residents received their medical and psychological care from health care centres that are part of or affiliated to the service providers' organisations. All service providers were staffed with support professionals, nurses, behavioural scientists and physicians. In case of severe mental disorders, clinicians could consult or refer to a psychiatrist. Some of the settings were training centres for the post-academic 3-year specialist training of ID physicians and in this way affiliated to university medical centres.
Participants were people with ID who used one or more antipsychotic drugs for at least a year, which were prescribed by ID physicians or trainees (16 in total). In one service provider, there was no ID physician available; here, an experienced general practitioner was responsible for the prescription of psychotropic drugs.
Procedure
In this study, we used the data of individuals that were considered for participation in a discontinuation trial of long-term (>1 year) used antipsychotics in people with ID, trial registration number NTR 201600374, which had been approved by our Medical Ethical Board. Data were collected in January and February 2015.
Dosage, duration of use and use of more than one antipsychotic drug simultaneously were retrieved from pharmaceutical and medical records for all antipsychotic drug users in the settings. Dosages were converted into defined daily dose (Rijcken et al. 2003) . Because of limitations in recording of the exact duration of use, this was categorised in <1, 1-5, 5-10 and >10 years.
We first asked the physicians to indicate whether the reason for prescription was based on (1) a clear diagnosis of schizophrenia, chronic psychotic disorder or affective psychosis according to the Diagnostic System Mental Disorders (DSM)-IV TR criteria, (2) less clear diagnoses of past or present transient episodes of psychotic symptoms or suspected psychosis and (3) non-psychosis-related challenging behaviours. We also recorded the client's age, sex, the living situation and severity of ID (categorised as profound, severe, moderate or mild according to DSM-IV TR criteria based on IQ test results available in the medical records). The living situation was categorised as 'nursing, care and support' (providing physical, mental and daily care), 'care and support' (providing mental and daily care) or 'support' (providing daily care).
In the sample of participants who were prescribed antipsychotics off-label (i.e. excluding those with a clear diagnosis of schizophrenia, chronic psychotic disorder or affective psychosis) and for long-term (i.e. >1 year), we subsequently asked their physicians whether they were eligible for drug discontinuation. If not, we asked the prescribing physicians to indicate whether this was based on (1) physicians' own considerations with regard to the mental status of the patient and the nature of the problem behaviour or considerations leading to lack of consent of (2) staff (the main caregiver and/or the behavioural scientist), (3) the patient and/or (4) the legal representative.
Finally, physicians were asked to indicate their objections against discontinuation on a form that included concerns that discontinuation of antipsychotics may lead to increase in (1) aggression, (2) restlessness, (3) hyperactivity, (4) anxiety, (5) distractibility and/or (6) self-injurious behaviour. Other objections could be (7) previous unsuccessful attempt(s) of discontinuation, (8) presence of autism spectrum disorder, (9) acquired brain injury, (10) dementia, (11) depressive mood and/or (12) other, among these changes in living environment, unfavourable living circumstances and temporary life events.
Statistical analyses
Pearson chi-squared test was used to investigate differences in frequencies of categorical variables and analyses of variance for differences in means of continuous variables. When variables were not normally distributed, we used the Kruskal-Wallis test. Univariate logistic regression analyses were used to investigate potential associations between 'physicians' decisions to discontinue the antipsychotic drug use' as dependent variable and data on antipsychotic drug use, participant characteristics and environmental characteristics as independent variables. Those variables that were associated with P < 0.2 were subsequently used in a multivariate logistic regression analysis. Because the independent categorical variables 'living situation' and 'service provider' were significantly associated with the dependent variable in the univariate analyses, here, we created dummy variables. Each of the three conditions of 'living situation' was set in contrast with 'missing' and each service provider in contrast with the five others. Duration of use and severity of ID were set as continuous variables. We used stepwise methods in the multivariate logistic regression analysis for the two blocks of dummy variables.
To assess the influence of setting culture on the odds for 'physicians' decisions to discontinue the antipsychotic drug use', we used univariate regression analyses for the six service providers dummy variables. Values of Exp(onentiated)(B), that is, the odds in logistic regression analyses, are reported with confidence intervals (CIs). The Hosmer and Lemeshow test was used to assess the goodness of fit for the multivariate prediction model for discontinuation of antipsychotics. We used P < 0.05 as a threshold for a significant association.
Results
Of the 3299 clients, 977 in the residential facilities used one or more antipsychotic drugs at the reference date (1 January 2015). Prevalence of antipsychotic drug use was 29.6% (95% CI 28.1-31.2%). Prevalence of antipsychotic drug use in the residential populations of the six service providers ranged from 24.8% to 38.3%. Table 1 shows characteristics of antipsychotic drugs users of the whole sample and by service provider. Participant characteristics varied considerably by service provider, as were decisions of physicians to discontinue the prescription of off-label long-term used antipsychotics. Overall, in just over half of the participants, the treating physician decided that the treatment with antipsychotics could be discontinued. Table 2 shows the different odds for 'physicians' decisions to discontinue the antipsychotic drug use' by service provider and reasons for decisions of physicians not to discontinue. In most cases, decisions not to discontinue in case of long-term offlabel use were based on physicians' own considerations; however, in some service providers, decisions were also considerably based on lack of consent to discontinue of the legal representative. In service providers 5 and 6, reasons of physicians not to discontinue their off-label antipsychotic drug prescriptions were missing or not recorded. Here, the odds for physicians' decisions to discontinue the antipsychotic drug use were highest. Furthermore, in service provider 1, 'other reasons' for objections were highest. Here, relocation of living facilities and changes in staff were major causes.
Associations between the independent variables related to antipsychotic drug use, participant characteristics, and environmental characteristics and the dependent variable 'physicians' decisions to discontinue the antipsychotic drug use'.
We did not include physicians' reasons not to discontinue the antipsychotic drug use as variable because of too much missing data ( Table 2 ). Variables that were associated with P < 0.2 in univariate analyses were used in the multivariate logistic regression analysis. These variables were duration of use, use of >1 antipsychotic drug simultaneously, reason for prescription, age, severity of ID and the dummy variable blocks 'living situation' and 'service provider'. In the model, 'challenging behaviour' as reason for prescription (Exp(B) = 0.11; CI = 0.06-0.20, P < 0.001), the living situation 'care and support' (Exp(B) = 1.50; CI = 1.03-2.19, P = 0.04) and the service providers 4 (Exp(B) = 2.66; CI = 1.25-5.65, P = 0.01), 5 (Exp(B) = 13.58; CI = 5.79-31.82, P = <0.001) and 6 (Exp(B) = 17.41; CI = 8.15-37.17, P < 0.001) were positively, and service provider 3 (Exp(B) = 0.31; CI = 0.20-0.48) was negatively associated with 'physicians' decisions to discontinue the antipsychotic drug use'. The Hosmer and Lemeshow test showed that the model predicted a decision to discontinue in 79.4% and not to discontinue in 68.5% correctly.
Discussion
In this study, in a population of 3299 persons with ID in living facilities of six service providers, we found a prevalence of 29.6% (CI 28.1-31.2%) antipsychotic drug use, which is similar to the 2008 prevalence of 32.2% in living facilities of three service providers (CI 30.1-33.9%) that we previously reported (de Kuijper, Hoekstra et al. 2010) . Prescriptions were off-label in a majority; only 5% were antipsychotic drugs prescribed for schizophrenia or a chronic psychotic disorder according to DSM-IV TR criteria, in 25% for (suspected) non-schizophrenia-related psychotic symptoms present or past and in 69% for problem challenging behaviour. Because transient or suspected non-schizophrenia-related psychotic symptoms and challenging behaviours are no licensed indications for chronic use of antipsychotics, we may conclude that off-label prescriptions are as high as 95%. Despite this, in just 51% of cases, the treating physicians decided that the long-term off-label use of antipsychotics in their clients could be discontinued. We found that 'challenging behaviour' as reason for prescription and the living situation 'care and support' were positively associated with physicians' decisions to discontinue the antipsychotic drug use of their patients. Currently, in the Netherlands, it has been widely accepted that long-term prescriptions of antipsychotics for challenging behaviour in absence of a psychotic disorder in people with ID should be avoided as much as possible. Furthermore, it may be presumed that the living situation 'care and support' is most frequent in those people who are moderately or severely intellectually disabled in absence of severe comorbid mental or physical conditions.
The likelihood for positive decisions of physicians to discontinue their off-label prescriptions and the influence of setting culture and beliefs of physicians on reasons for a negative decision differed largely between the settings. A remarkable finding was the high frequency of '(suspected) non-schizophrenia related psychotic-symptoms present or past' as reason for long-term prescription of antipsychotics in service provider 4, which was in contrast with the other service providers where 'problem behaviour' was the main reason. This difference may be explained by the lack of an ID physician in service provider 4. Here, a general practitioner was responsible for the prescription of psychotropic drugs. Although the prescriptions were apparently off-label, diagnostic uncertainties and concerns for psychotic symptoms may explain the low odds for a positive decision to discontinue in this service provider. The odds for a positive decision to discontinue were highest in service providers 5 and 6. Service providers 5 and 6 were no training centres, and although they had no academic affiliations, here, the ID physicians may have more experience in assessment and evidencebased treatments of mental disorders than in the other settings where supervised intellectualdisability-physician-trainees also provided the mental health care.
There was a wide variety in the reasons for negative decisions of physicians regarding discontinuation. This may be explained by differences in attitudes and beliefs of settings' staff towards off-label antipsychotic drug use in people with ID. Differences in prescriptions between settings and between prescribers were also found in other studies. Huskamp et al. found differences between younger and older prescribers and between rural versus nonrural areas. A difference between prescribers was also found by Tang et al. (2016) and between settings in a Canadian study (Arora, Knowles, Gomes, Mamdani, Juurlink, Carlisle et al. 2016) . Results of the present study confirm results of another study in which it was shown that polypharmacy prescription patterns of physicians were largely independent of patient characteristics and were partly driven by hospitals' and physicians' propensities to prescribe in this way (Latimer, Naidu, Moodie, Clark, Malla, Tamblyn et al. 2014) . Furthermore, some studies have shown differences between prescribers with regard to work setting (academic versus nonacademic) and research activities (Chang, Kim 2014) , attitudes and beliefs towards effects of antipsychotics (Kishimoto et al. 2013 ) and evidence-based orientations (Eguale et al. 2012) .
A strength of this study was the relatively large sample size, even for each individual service provider. Therefore, we think the results of this study may well apply to other service providers for people with ID in the Netherlands and beyond with regard to prevalence of antipsychotic drug use, differences between settings regarding physicians' willingness to consider discontinuation of off-label used antipsychotics and reasons of physicians for ongoing prescriptions. A limitation was that we did not collect data on setting cultures like evidence-based orientations, policies in adherence to psychotropic drug prescription guidelines and on physicians' attitudes and beliefs towards effects of antipsychotics for behavioural symptoms in people with ID. Also, it should be acknowledged that in some cases, there were no legal representatives of clients to share the decision whether or not to discontinue the antipsychotic drug treatment. Here, we had to rely solely on judgements of staff professionals, including the treating physician and the client himself or herself.
The results of this study give rise to two major points that need to be taken into consideration. The first point to consider is the differences between service providers in decisions of physicians to discontinue off-label and mostly not evidence-based prescriptions of antipsychotic drugs in people with ID. In general, such a large variation in clinical practice among physicians should preferably be avoided, because of the potential of inequalities in the quality of care among patients. Probably, several underlying factors may play a role here, including organisational factors, diagnostic uncertainties, attitudes, beliefs and knowledge towards antipsychotic drug use of treating physicians and other staff and communication of staff with clients and their representatives. Studies in these underlying factors are needed in order to stimulate equality of care regardless of service providers and an evidencebased practice in ID mental health care.
The second major point to consider is the reasoning of physicians, behavioural scientists and last but not the least, legal representatives for ongoing long-term treatments. Aggression, restlessness, autism spectrum disorders, 'other reasons' (among these, lack of appropriate environmental circumstances) and previously unsuccessful discontinuation trajectories were all frequently mentioned reasons. In previous studies, it was shown that symptoms of autism may benefit from treatment with antipsychotics, although the quality of the studies was generally poor (Tsiouris et al. 2013 , Deb et al. 2014 , Wink et al. 2015 , Park et al. 2016 . Thus, autism as reason not to discontinue may be a valid reason in some cases. Furthermore, although there is no evidence base for the effectiveness of antipsychotic drugs to manage problem behaviours in the absence of a psychiatric disorder (Deb, Kwok, Bertelli, Salvador-Carulla, Bradley, Torr et al. 2009 ), there might be undiagnosed psychiatric disorders or mental symptoms manifesting in, for example, restlessness in especially those more severely intellectually disabled people, which may be reduced by a treatment with antipsychotics. This may be illustrated by the finding of Paton et al. (2011) that the frequency of prescriptions of antipsychotics without a record of mental illness increased with severity of ID. Studies on the effectiveness and safety of antipsychotic drugs on well-defined mental and behavioural symptoms are needed to establish a better evidence base for antipsychotic drug treatments in this subgroup of people with ID.
Conclusion
In this study on prevalence and environmental factors related to reasons for ongoing off-label antipsychotic drug use of people with ID in six service providers spread over the Netherlands, we found a prevalence of almost 30% antipsychotic drug use. In 95% of cases, the use was off-label and in 96% of cases with a duration of more than 1 year. In 51% of those, 96% long-term users' physicians decided the treatment could be discontinued, mostly in off-label indications.
'Challenging behaviour' as reason for prescription and a living situation with 'care and support', meaning that participants received support for their mental health needs and activities of daily life, were associated with a higher likelihood for positive decisions to discontinue.
Physicians' willingness to discontinue varied largely across service providers, likely because of differences in setting cultures regarding physicians attitudes and beliefs on effects of antipsychotics in people with ID and the influence on physicians' decisions of other persons involved with the care of participants. Unsuccessful previous attempts to discontinue, concerns for symptoms of restlessness and the presence of autism spectrum disorders were reasons for decisions no to discontinue.
Education and training in evidence-based practice in assessments and treatments of mental disorders in people with ID are warranted for physicians and behavioural scientists who are responsible for the mental health care in this population. Also, professionals should pay more attention to informed consent procedures in this population. Service providers should facilitate these and other necessary changes in setting cultures. Furthermore, studies on the effectiveness and safety of antipsychotic drugs for well-defined mental and behavioural symptoms in case it is not possible to establish psychiatric diagnoses are needed.
Funding
